



**Pfizer Limited**

The Capital, 1802/1901,  
Plot No. C - 70, G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.  
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

February 1, 2025

The Corporate Relationship Dept.  
BSE Limited  
1<sup>st</sup> Floor, P.J.Towers  
Dalal Street, Fort  
Mumbai – 400 001  
Scrip Code: 500680

The Manager, Listing Dept.  
The National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1,  
G Block Bandra-Kurla Complex, Bandra (E)  
Mumbai – 400 051  
Scrip Symbol: PFIZER

Dear Sirs,

**Sub: Integrated Filing (financial) for the quarter and nine months ended December 31, 2024.**

Pursuant to the Securities and Exchange Board of India circular dated December 31, 2024, we attached herewith the Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024.

We request you to kindly take the same on record.

Thanking you,

Yours truly,  
**For Pfizer Limited**

**Prajeet Nair**  
**Director – Corporate Services & Company Secretary**

**Cc.: National Securities Depository Limited (NSDL)**  
**Central Depository Services (India) Limited (CDSL)**  
**KFin Technologies Limited**

**CIN:** L24231MH1950PLC008311  
**Email ID:** [contactus.india@pfizer.com](mailto:contactus.india@pfizer.com)  
**Website:** [www.pfizerltd.co.in](http://www.pfizerltd.co.in)



**Pfizer Limited**  
 The Capital, 1802/1901,  
 Plot No. C - 70, G Block, Bandra Kurla Complex,  
 Bandra (East), Mumbai 400 051.  
 Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

**Statement of Unaudited Financial Results for the Quarter and Nine months ended 31 December 2024**

(₹ in crore except earnings per share)

| Particulars   | 3 months ended<br>31/12/2024 | Preceding 3 months<br>ended<br>30/09/2024 | Corresponding 3<br>months ended in<br>the previous year<br>31/12/2023 | Year to date figures<br>for nine months<br>ended<br>31/12/2024 | Year to date<br>figures for nine<br>months ended<br>31/12/2023 | Previous year<br>ended<br>31/03/2024 |
|---|------------------------------|---|---|--|--|--------------------------------------|
|   | Unaudited                    | Unaudited                                 | Unaudited   | Unaudited  | Unaudited  | Audited                              |
| <b>1 Income</b>   |                              |   |   |  |  |                                      |
| (a) Revenue from operations   | 537.99                       | 588.59                                    | 539.97  | 1,689.44   | 1,646.54   | 2,193.17                             |
| (b) Other income  | 42.76                        | 43.07                                     | 35.85   | 127.67   | 105.38   | 180.51                               |
| <b>Total income</b>   | <b>580.75</b>                | <b>631.66</b>                             | <b>575.82</b>   | <b>1,817.11</b>  | <b>1,751.92</b>  | <b>2,373.68</b>                      |
| <b>2 Expenses</b>   |                              |   |   |  |  |                                      |
| (a) Cost of materials consumed  | 67.31                        | 76.65                                     | 77.23   | 201.70   | 247.12   | 335.80                               |
| (b) Purchases of stock-in-trade   | 104.99                       | 80.65                                     | 148.60  | 373.23   | 374.63   | 468.59                               |
| (c) Changes in inventory of finished goods, work-in-progress and stock-in-trade | 24.26                        | 53.42                                     | (43.27)   | 33.04  | (18.52)  | (11.82)                              |
| (d) Employee benefits expense   | 96.29                        | 100.76                                    | 89.37   | 288.42   | 272.69   | 347.80                               |
| (e) Finance costs   | 1.51                         | 2.10                                      | 2.86  | 5.72   | 8.46   | 15.41                                |
| (f) Depreciation and amortization expense                                       | 14.80                        | 14.99                                     | 17.55   | 44.39  | 48.53  | 62.28                                |
| (g) Other expenses  | 99.15                        | 87.86                                     | 115.49  | 280.32   | 324.75   | 417.50                               |
| <b>Total expenses</b>   | <b>408.31</b>                | <b>416.43</b>                             | <b>407.83</b>   | <b>1,226.82</b>  | <b>1,257.66</b>  | <b>1,635.56</b>                      |
| <b>3 Profit before tax and exceptional items (1 - 2)</b>                        | <b>172.44</b>                | <b>215.23</b>                             | <b>167.99</b>   | <b>590.29</b>  | <b>494.26</b>  | <b>738.12</b>                        |
| <b>4 Exceptional items (Refer Note 5)</b>                                       | -                            | -   | 7.95  | -  | 7.95   | 7.95                                 |
| <b>5 Profit before tax (3 + 4)</b>  | <b>172.44</b>                | <b>215.23</b>                             | <b>175.94</b>   | <b>590.29</b>  | <b>502.21</b>  | <b>746.07</b>                        |
| <b>6 Tax expense</b>  |                              |   |   |  |  |                                      |
| (a) Current tax   | 50.10                        | 59.89                                     | 29.17   | 165.04   | 109.94   | 158.92                               |
| (b) Deferred tax  | (5.26)                       | (3.01)                                    | 16.79   | (11.41)  | 19.80  | 36.11                                |
| (c) Tax adjustments for earlier years   | -                            | -   | -   | -  | -  | (0.29)                               |
| <b>7 Net profit for the period / year (5 - 6)</b>                               | <b>127.60</b>                | <b>158.35</b>                             | <b>129.98</b>   | <b>436.66</b>  | <b>372.47</b>  | <b>551.33</b>                        |
| <b>8 Other comprehensive income</b>   |                              |   |   |  |  |                                      |
| (a) Items that will not be reclassified subsequently to profit or loss          | (0.72)                       | (0.71)                                    | (1.11)  | (2.15)   | (3.31)   | 7.28                                 |
| (b) Income tax related to items that will not be reclassified to profit or loss | 0.18                         | 0.18                                      | 0.28  | 0.54   | 0.83   | (1.83)                               |
| <b>Other comprehensive income, net of taxes</b>                                 | <b>(0.54)</b>                | <b>(0.53)</b>                             | <b>(0.83)</b>   | <b>(1.61)</b>  | <b>(2.48)</b>  | <b>5.45</b>                          |
| <b>9 Total comprehensive income for the period / year (7 + 8)</b>               | <b>127.06</b>                | <b>157.82</b>                             | <b>129.15</b>   | <b>435.05</b>  | <b>369.99</b>  | <b>556.78</b>                        |
| <b>10 Paid-up equity share capital (Face value per share ₹10)</b>               | <b>45.75</b>                 | <b>45.75</b>                              | <b>45.75</b>  | <b>45.75</b>   | <b>45.75</b>   | <b>45.75</b>                         |
| <b>11 Other equity</b>  |                              |   |   |  |  | <b>3,549.79</b>                      |
| <b>12 Earnings per share - Basic and Diluted (of ₹10/- each) #</b>              |                              |   |   |  |  |                                      |
| Computed on the basis of net profit for the period / year                       | 27.89                        | 34.61                                     | 28.42   | 95.44  | 81.42  | 120.51                               |
| <b># Earnings per share - Basic and Diluted before Exceptional items</b>        | <b>27.89</b>                 | <b>34.61</b>                              | <b>27.12</b>  | <b>95.44</b>   | <b>80.12</b>   | <b>119.22</b>                        |

\*Not annualised

CIN: L24231MH1950PLC008311  
 Email ID: [contactus.india@pfizer.com](mailto:contactus.india@pfizer.com)  
 Website: [www.pfizerindia.co.in](http://www.pfizerindia.co.in)

M. Kumar

**NOTES:**

1. The above financial results were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on January 31, 2025.
2. The standalone financial results of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time).
3. The Company does not have any subsidiary company or associate company or joint venture company as at December 31, 2024.
4. The financial results for the quarter and nine months ended December 31, 2024 have been subject to Limited Review by the Statutory Auditors of the Company. The Limited Review report does not contain any modifications. The Limited Review report will be filed with the Stock Exchanges and will also be available on the Company's website - [www.pfizerltd.co.in](http://www.pfizerltd.co.in)
5. Exceptional item for the quarter and nine months ended December 31, 2023 and year ended March 31, 2024 is in relation to provision for old pending VAT / CST litigations. The Company opted for Maharashtra VAT Amnesty Scheme for certain years and had received final settlement orders. Pursuant to the said orders, the Company had written back excess provision of ₹ 7.95 crore.
6. The Company had intended to transfer its unexpired leasehold rights in the Maharashtra Industrial Development Corporation ("MIDC") Land and Sale of Buildings constructed on such land at Thane and accordingly, it was classified as 'Asset held for sale'. During the quarter ended December 31, 2023, the Company had entered into an Agreement to Assign and Assume the Lease of MIDC Land and Sale of Buildings constructed on such land to Zoetis Pharmaceutical Research Private Limited, for a lumpsum consideration of ₹ 264.40 crore, of which ₹ 52.88 crore was received as an advance. During the quarter ended December 31, 2024, the Company has received a direction from MIDC to pay charges towards transfer and to comply with certain conditions. Completion of transaction is subject to the final approval from MIDC and hence effect of the said agreement has not been given in these financial results.
7. The Company has only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segments is not applicable and accordingly not made.

January 31, 2025

For Pfizer Limited



Meenakshi Nevatia  
Managing Director

# B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing  
Nesco IT Park 4, Nesco Center  
Western Express Highway  
Goregaon (East), Mumbai – 400 063, India  
Telephone: +91 (22) 6257 1000  
Fax: +91 (22) 6257 1010

## Limited Review Report on unaudited financial results of Pfizer Limited for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

### To the Board of Directors of Pfizer Limited

1. We have reviewed the accompanying Statement of unaudited financial results of Pfizer Limited (hereinafter referred to as "the Company") for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022

**Sadashiv Shetty**

Partner

Membership No.: 048648

UDIN:25048648BMNYHC1291

Mumbai

31 January 2025

- A. **STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC:** Not applicable
- B. **FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES:**  
Not applicable
- C. **FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (APPLICABLE ONLY FOR HALF-YEARLY FILINGS i.e 2ND AND 4TH QUARTER):** Not applicable
- D. **STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG WITH ANNUAL AUDITED FINANCIAL RESULTS (STANDALONE AND CONSOLIDATED SEPARATELY) (APPLICABLE ONLY FOR ANNUAL FILING i.e 4TH QUARTER):** Not applicable